Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Please email charlotte.bell@medsci.ox.ac.uk if you would like to meet Andy. Please send a short description of what you would like to discuss.

Andy is available to have non-confidential discussions and offer advice on:

  • Drug discovery spanning target identification and validation through to early clinical development
  • Routes to progress drug discovery and translational projects
  • Career development for early career researchers
  • Andy’s role is not to scout for projects for GSK, or give GSK’s angle on projects – please bear this in mind when setting up an appointment. 

More about Andy: 

Andy is Scientific Director in the Novel Human Genetics Research Unit in GSK, a department dedicated to identifying and validating targets based on genetic data, and then executing drug discovery to identify new candidate medicines. Andy joined GSK as Director, Discovery Partnerships with Academia in 2014 after working in the Respiratory Therapy Area at Novartis. Andy has led multiple drug discovery projects from target nomination and hit identification through to selection of high quality clinical candidates. Andy has experience of programs of all major target classes, of localised and oral drug delivery and both small molecule and biopharmaceutical modalities. Andy is a Fellow of the Royal Society of Biology and gives classes on drug discovery to undergraduate / MSc students at Cambridge and Oxford Universities. With over 18 years of experience in target and drug discovery in academia and Pharma companies Andy is well placed to provide advice and guidance on those areas listed above. A biochemist and cell biologist by training, Andy received his undergraduate degree and DPhil from the University of Oxford and undertook postdoctoral studies at the University of Birmingham, identifying and studying novel membrane receptors and their signal transduction pathways.